Download Eeva – the Early Embryo Viability Assessment Test

Eeva – the Early Embryo Viability Assessment Test
INFERTILITY – A GLOBAL HEALTH ISSUE
More than
72
million women
around
the world
are estimated to be
affected by infertility,
a condition of the
reproductive system1
Approx.
56%
of women
facing infertility issues
seek medical assistance1
IVF OUTCOMES STRONGLY DEPEND ON ROUTINES AND TECHNOLOGIES APPLIED IN IVF LABORATORIES
There are several factors during the IVF treatment journey that contribute to a successful
live birth, including IVF drug treatment as well as technologies applied in the IVF laboratories.
Among the latter, gamete assessment and preservation, fertilization and embryo cultivation,
assessment and preservation are key steps.
PREGNANCY
TESTING
CONSULTATION
IVF DRUG
TREATMENT
OOCYTE &
SPERM MGMT.
& ANALYSIS
OOCYTE & SPERM
PRESERVATION
FERTILIZATION
EMBRYO
CULTIVATION AND
ASSESSMENT
PRESERVATION
(EMBRYO)
OOCYTE
AND SPERM
RETRIEVAL
EARLY
PREGNANCY
SUPPORT
EMBRYO
TRANSFER
Due to the complex IVF workflow, it is essential to standardise and automate lab procedures and
applied technologies, thereby ensuring consistency and objectivity in decision making, and maximizing
the chances of IVF success.2
RH15-0029bf November 2015 1 of 3
Dedicated to the details that matter
Eeva – the Early Embryo Viability Assessment Test
EEVA
The Early Embryo Viability
Assessment (Eeva™)
Early stage
Eeva™ is designed to improve IVF
outcomes at an early stage when used in
conjunction with traditional morphology
•innovative and non-invasive
•used by IVF laboratories
•analyses embryo development
Quantitative data
•on embryo’s potential development
•optimizes IVF treatment path
HOW DOES IT WORK?
Eeva™ is a non-invasive embryo assessment test
•enabled by a microscope equipped with a time-lapse
camera with dark field illumination
•fits into most standard incubators used in clinics
The true innovation of Eeva™ is in its
proprietary software:
•automatically analyses embryo development
•is built upon a unique predictive algorithm
i
Eeva™ provides medical staff with objective
information on the development and viability
of the embryos on day three after fertilisation
The test helps identify embryos that
have a high potential to become blastocysts*3
* an embryo that has developed for five to six days after fertilization
EMBRYOS GROWING IN THE
SPECIALLY DESIGNED EEVA DISH
Embryo
viability
DAY 3-5
Embryoblast
BLASTOCYST STAGE
RH15-0029bf November 2015 2 of 3
Dedicated to the details that matter
Eeva – the Early Embryo Viability Assessment Test
The Eeva™ test was validated in a
prospective, multicentre clinical trial
with a total of 74 patients and
941 embryos* 3
Eeva™ used adjunctively to traditional
methodology was able to predict
blastocyst formation at the cleavage
stage with
85%
specificity* 3
*measurement of
ability to predict
embryos that
became usable
blastocysts
Eeva used adjunctively to traditional
methodology was able to reduce the false
positive rate (test result falsely indicates
that an embryo has a high viability) from
43% to 15% compared with traditional
morphological methods alone4
Additionally, Eeva™ was able to increase
the consistency of embryo assessment
across embryologists3
1 Boivin J. et al. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007 Jun;22(6):1506-12. 2 Olofsson JI. et. al.Quality
management systems for your in vitro fertilization clinic's laboratory: Why bother? J Hum Reprod Sci. 2013 Jan-Mar; 6(1): 3–8. available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713573/ Accessed Nov
2015 3 Conaghan et al. Improving embryo selection using computer-automated time-lapse imaging plus day 3 morphology: results from a prospective multi-center trial. Fertility and Sterility: 2013;100:412-9.
4 Wong et al. Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage. Nature Biotechnology, 2010;28:1115-21.
The Eeva Test is available through Merck in the UK. The Eeva Test was in-licensed in 2014 from Auxogyn Inc.
RH15-0029bf November 2015 3 of 3
Dedicated to the details that matter